Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B S Graham

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.
Vaccine|November 2, 2010
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsJ E Ledgerwood, P Costner, N Desai, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
Journal of Virology|January 28, 1998
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesR I Connor, B T Korber, B S Graham, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Clinical and Experimental Immunology|September 3, 2015
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adultsJ E Ledgerwood, E E Coates, G Yamshchikov, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.
Vaccine|November 2, 2010
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsJ E Ledgerwood, P Costner, N Desai, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
Journal of Virology|January 28, 1998
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesR I Connor, B T Korber, B S Graham, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Clinical and Experimental Immunology|September 3, 2015
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adultsJ E Ledgerwood, E E Coates, G Yamshchikov, et al.
Pageof 14